FDA delays meeting on kid vaccines as Pfizer promises more data
The regulators suggested the interim data was insufficient to begin considering authorization of the vaccine before the trial of three doses is complete. Pfizer and BioNTech said in a statement they expect data on the three-dose regimen by early April. “Being able to begin evaluating initial data has been useful in our review of these … Read more
